Sesame Summit 2026 – application open

Generare raises €20 million to unlock novel molecules from microbial genomes

Europe’s biotechnology sector is experiencing a significant structural shift in how the pharmaceutical industry approaches early-stage drug discovery. For decades, the pipeline of novel chemical compounds has been constrained not by a shortage of analytical tools or computational power, but by a fundamental scarcity of genuinely new molecular data. Approximately 97% of the genomic information encoded within microbial life remains unexplored — a largely untapped reservoir of chemical diversity that holds considerable promise for addressing medicine’s most persistent challenges, from antimicrobial resistance to oncology. Paris-based Generare has raised €20 million in Series A funding to systematically unlock that potential.

The round was co-led by Alven and Daphni, two of France’s most active venture capital firms in the life sciences and deep tech space, with continued participation from all existing investors: Galion.exe, Teampact Ventures, and VIVES Partners. The capital will be used to scale Generare’s discovery capacity tenfold by 2027 — targeting a library of more than 2,000 novel compounds — and to grow the team from 25 to approximately 50 specialists spanning computational biology, synthetic biology, chemistry, and engineering.

Strategic investors back Europe’s molecular discovery push

The investment thesis behind the round reflects a growing recognition that drug discovery’s bottleneck lies upstream of the algorithm. As Guillaume Vandenesch, co-founder and CEO of Generare, stated: “Drug discovery has a data problem. The bottleneck is not algorithms — it is the absence of genuinely novel, high-quality molecular data.” Vandenesch co-founded the company in 2023 alongside Dr Vincent Libis, a specialist in natural product biosynthesis, on the premise that the world’s microbial genomes represent a systematically underexploited source of bioactive chemistry.

Generare’s platform reads microbial genomes at scale, identifies gene sequences with the highest likelihood of producing bioactive molecules, expresses them in laboratory conditions, and characterises the resulting compounds for structure, biological activity, and drug potential. The output is a growing, proprietary library of molecules that pharmaceutical companies can access through licensing or partnership arrangements. The participation of Alven — a long-standing investor in French deep tech — and the entry of Daphni signal confidence that the platform has cleared early technical risk and is ready for industrial scaling.

Results to date support that assessment. During 2025, Generare independently identified more than 200 previously unknown molecules. To put that in context: across the same period, all other players in the natural product discovery space collectively discovered just a few dozen. That differential speaks directly to the industrial nature of the platform Generare has built — not a research tool, but a molecule-generating engine.

European biotech market context

The broader European biotechnology market is displaying resilience in early 2026, with Series A rounds in the €15–30 million range increasingly common for platform companies that can demonstrate early IP validation and a differentiated data asset. Microbial genomics specifically is attracting growing institutional attention: the global microbial genomics market is projected to expand from approximately $2.5 billion in 2025 to $4.6 billion by 2030, at a compound annual growth rate of 13%, driven by advances in sequencing technology and the pharmaceutical industry’s urgent need for diversified compound libraries.

France has emerged as a particularly active node in European biotech investment. Earlier this year, the country’s life sciences sector produced a series of notable early-stage rounds, reflecting both the depth of its research base and the maturity of its venture capital ecosystem. Generare’s raise adds to a mounting body of evidence that Paris-based deep tech platforms are increasingly able to attract capital at meaningful scale for genuinely novel science. For comparable recent activity in European biotech fundraising, Scripta Therapeutics’ €10.3 million seed round earlier this year illustrates the investor appetite for differentiated drug development platforms across the continent.

With the Series A secured, Generare is positioned to transition from an early-stage research platform to a scalable molecular discovery engine. The company’s longer-term ambition extends to identifying more than 10,000 novel compounds — a scale that, if achieved, would make it one of the most productive sources of new drug candidates in Europe. For a sector that has long grappled with high late-stage clinical attrition, richer upstream molecular data represents a meaningful structural improvement to the entire discovery chain.


<

CompanyGenerare (Generare Bioscience SAS)
HQParis, France
Founded2023
RoundSeries A
Amount€20 million (~$23.2 million)
Lead InvestorsAlven, Daphni
Co-InvestorsGalion.exe, Teampact Ventures, VIVES Partners
Use of FundsScale compound library to 2,000+ molecules by 2027; grow team from 25 to ~50
Company Websitehttps://generare.bio/

you might also like

Fundraising 3 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.